Katherine Riester

发表

Safety and Tolerability Results From the DECIDE Study: A Phase 3 Active-Comparator Study of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis (P7.230)

Ludwig Kappos, Douglas L. Arnold, John W. Rose, 2015 .

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

Gavin Giovannoni, Xavier Montalban, Ernst-Wilhelm Radue, 2013, The Lancet.